Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
August 26, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO),...
Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
August 15, 2022 16:05 ET
|
Sema4
New management team implements significant restructuring to focus on profitable growth, efficiency, and scale 19% pro forma1 volume growth vs. 2Q 2021 Sema4 to host a conference call today...
Sema4 Announces Changes to its Research & Development Leadership
August 15, 2022 16:05 ET
|
Sema4
Founder Eric Schadt steps down from the organization, including his role as President & Chief R&D Officer Matthew Davis named Chief Technology & Product Officer to further drive the...
Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
July 26, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 Announces Chief Financial Officer Transition Plan
June 14, 2022 16:30 ET
|
Sema4
Appoints Richard Miao, Sema4’s Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE...
Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area
June 01, 2022 08:30 ET
|
Sema4
SIOUX FALLS, S.D. and STAMFORD, Conn., June 01, 2022 (GLOBE NEWSWIRE) -- Avera Health, an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4...
Sema4 to Participate at Two Investor Conferences in June 2022
May 26, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4 Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 16:05 ET
|
Sema4
Total revenue of $53.9 million 1,300 basis points of sequential adjusted gross margin improvement Reaffirming full year 2022 pro forma revenue target New operating model and focus on efficiencies...
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
May 02, 2022 07:45 ET
|
Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...